|Title:||Orally administrable opioid formulations having extended duration of effect|
|Abstract:||Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in sustained release form. The substrates have a diameter from about 0.1 mm to about 3 mm.|
|Inventor(s):||Oshlack; Benjamin (New York, NY), Chasin; Mark (Manalapan, NJ)|
|Assignee:||Purdue Pharma L.P. (Stamford, CT)|
Patent Claim Types:|
see list of patent claims
Field: Not categorized
Back Citations: 90th percentile
Forward Citations: 1st percentile
|Patent Number||Expiration Date|
|6,294,195||September 25, 2013|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.